Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
March 12, 2020 16:45 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at Upcoming Investor Conferences
November 13, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference
October 01, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
September 12, 2019 16:05 ET
|
Translate Bio, Inc.
-- Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE)...
Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
July 31, 2019 06:51 ET
|
Translate Bio, Inc.
-- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into clinical development,...
Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
July 31, 2019 06:50 ET
|
Translate Bio, Inc.
-- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume...
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
July 15, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
June 26, 2019 07:00 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the Jefferies 2019 Healthcare Conference
May 28, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces $47.5 Million Private Placement
May 01, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...